Subscribe to RSS
DOI: 10.1055/s-0037-1604165
Neurosarcoidosis
Publication History
Publication Date:
27 July 2017 (online)
![](https://www.thieme-connect.de/media/srccm/201704/lookinside/thumbnails/10-1055-s-0037-1604165_01303-1.jpg)
Abstract
Neurosarcoidosis is an uncommon but clinically significant manifestation that will be routinely encountered in sarcoidosis specialty clinics. Overall, neurologic involvement is recognized in 5 to 10% of individuals with sarcoidosis. Neurologic symptoms will be the presenting manifestation of sarcoidosis in approximately one-half of those with neurosarcoidosis. The clinical and imaging features of neurosarcoidosis vary widely, largely depending on the anatomic distribution of the disease. The likelihood of spontaneous resolution is lower than for sarcoidosis in general, and residual functional deficits are not uncommon. Therefore, most patients with neurosarcoidosis require immunosuppressive therapy. Small fiber neuropathy, a recently recognized nongranulomatous parasarcoidosis syndrome, is prevalent in chronic sarcoidosis. The variety of neurologic manifestations, broad differential diagnosis, and complexity of management render neurosarcoidosis an area best served by multidisciplinary teams. Sarcoidologists, neurologists, radiologists, neurosurgeons, endocrinologists, urologists, physiatrists, and physical/occupational therapists all potentially have important roles.
-
References
- 1 Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157 (16) 1864-1868
- 2 Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42 (09) 909-917
- 3 Baughman RP, Teirstein AS, Judson MA. , et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10, Pt 1): 1885-1889
- 4 Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol 2016; 16 (01) 220
- 5 Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 1993; 43 (7-8): 372-376
- 6 Waxman JS, Sher JH. The spectrum of central nervous system sarcoidosis. A clinical and pathologic study. Mt Sinai J Med 1979; 46 (03) 309-317
- 7 Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001; 248 (05) 363-372
- 8 Chapelon C, Ziza JM, Piette JC. , et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990; 69 (05) 261-276
- 9 Zajicek JP, Scolding NJ, Foster O. , et al. Central nervous system sarcoidosis--diagnosis and management. QJM 1999; 92 (02) 103-117
- 10 Leonhard SE, Fritz D, Eftimov F, van der Kooi AJ, van de Beek D, Brouwer MC. Neurosarcoidosis in a tertiary referral center: a cross-sectional cohort study. Medicine (Baltimore) 2016; 95 (14) e3277
- 11 Nozaki K, Scott TF, Sohn M, Judson MA. Isolated neurosarcoidosis: case series in 2 sarcoidosis centers. Neurologist 2012; 18 (06) 373-377
- 12 Inoue Y, Inui N, Hashimoto D. , et al. Cumulative incidence and predictors of progression in corticosteroid-naive patients with sarcoidosis. PLoS One 2015; 10 (11) e0143371
- 13 Christoforidis GA, Spickler EM, Recio MV, Mehta BM. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 1999; 20 (04) 655-669
- 14 Judson MA, Baughman RP, Thompson BW. , et al; ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20 (03) 204-211
- 15 Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand 1986; 73 (03) 283-290
- 16 Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102 (07) 449-460
- 17 Raza N, Schreck KC. Neurosarcoidosis presenting with recurrent strokes: a case report and literature review. Neurohospitalist 2017; 7 (02) 91-95
- 18 Brisman JL, Hinduja A, McKinney JS, Gerhardstein B. Successful emergent angioplasty of neurosarcoid vasculitis presenting with strokes. Surg Neurol 2006; 66 (04) 402-404
- 19 Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med 1977; 87 (03) 336-345
- 20 James DG, Sharma OP. Neurosarcoidosis. Proc R Soc Med 1967; 60 (11, Part 1): 1169-1170
- 21 Oksanen V, Salmi T. Visual and auditory evoked potentials in the early diagnosis and follow-up of neurosarcoidosis. Acta Neurol Scand 1986; 74 (01) 38-42
- 22 Carlson ML, White Jr JR, Espahbodi M. , et al. Cranial base manifestations of neurosarcoidosis: a review of 305 patients. Otol Neurotol 2015; 36 (01) 156-166
- 23 Bansal S, Yin K, Vishwanath M, Doran H, Laitt R, Ansons A. Isolated pupil-involving third nerve palsy as the first presentation of sarcoidosis. Neuroophthalmology 2014; 38 (05) 278-280
- 24 Bangiyev L, Kornacki S, Mikolaenko I. Rare isolated trigeminal nerve sarcoidosis mimicking schwannoma. Clin Imaging 2015; 39 (01) 133-135
- 25 Shah R, Roberson GH, Curé JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol 2009; 30 (05) 953-961
- 26 Benzagmout M, Boujraf S, Góngora-Rivera F, Bresson D, Van-Effenterre R. Neurosarcoidosis which manifested as acute hydrocephalus: diagnosis and treatment. Intern Med 2007; 46 (18) 1601-1604
- 27 Colover J. Sarcoidosis with involvement of the nervous system. Brain 1948; 71 (Pt. 4): 451-475
- 28 Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci 2011; 1: 15
- 29 Miller DH, Kendall BE, Barter S. , et al. Magnetic resonance imaging in central nervous system sarcoidosis. Neurology 1988; 38 (03) 378-383
- 30 Smith AS, Meisler DM, Weinstein MA. , et al. High-signal periventricular lesions in patients with sarcoidosis: neurosarcoidosis or multiple sclerosis?. AJR Am J Roentgenol 1989; 153 (01) 147-152
- 31 Scott TF. Neurosarcoidosis: progress and clinical aspects. Neurology 1993; 43 (01) 8-12
- 32 Cohen-Aubart F, Galanaud D, Grabli D. , et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 2010; 89 (02) 133-140
- 33 Durel CA, Marignier R, Maucort-Boulch D. , et al. Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. J Neurol 2016; 263 (05) 981-990
- 34 Flanagan EP, Kaufmann TJ, Krecke KN. , et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79 (03) 437-447
- 35 Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci 2014; 347 (03) 195-198
- 36 Junger SS, Stern BJ, Levine SR, Sipos E, Marti-Masso JF. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 1993; 43 (02) 333-337
- 37 Tavee JO, Stern BJ. Neurosarcoidosis. Clin Chest Med 2015; 36 (04) 643-656
- 38 Varrassi M, Gianneramo C, Arrigoni F. , et al. Neurological involvement of IgG4-related disease: description of a case and review of the literature. Neuroradiol J 2017; 1971400917698173
- 39 Said G, Lacroix C, Planté-Bordeneuve V. , et al. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients. Brain 2002; 125 (Pt 2): 264-275
- 40 Burns TM, Dyck PJ, Aksamit AJ, Dyck PJ. The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases. J Neurol Sci 2006; 244 (1-2): 77-87
- 41 Vital A, Lagueny A, Ferrer X, Louiset P, Canron MH, Vital C. Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin Neuropathol 2008; 27 (02) 96-105
- 42 Singhal NS, Irodenko VS, Margeta M, Layzer RB. Sarcoid polyneuropathy masquerading as chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2015; 52 (04) 664-668
- 43 Shah JR, Lewis RA. Sarcoidosis of the cauda equina mimicking Guillain-Barré syndrome. J Neurol Sci 2003; 208 (1-2): 113-117
- 44 Mattiassich G, Schubert H, Hutarew G, Wechselberger G. A rare manifestation of sarcoidosis with sensomotoric neuropathy of the ulnar nerve as the only symptom. BMJ Case Rep 2012; 2012: pii : bcr2012007430
- 45 Verdú E, Ceballos D, Vilches JJ, Navarro X. Influence of aging on peripheral nerve function and regeneration. J Peripher Nerv Syst 2000; 5 (04) 191-208
- 46 Seddon HJ, Medawar PB, Smith H. Rate of regeneration of peripheral nerves in man. J Physiol 1943; 102 (02) 191-215
- 47 Bakkers M, Merkies IS, Lauria G. , et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009; 73 (14) 1142-1148
- 48 Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med 2017; 126: 135-138
- 49 Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011; 15 (03) 201-206
- 50 Chen X, Graham J, Dabbah MA. , et al. Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care 2015; 38: 1138-1144
- 51 Culver DA, Dahan A, Bajorunas D. , et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci 2017; 58 (06) BIO52-BIO60
- 52 Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75 (06) 568-570
- 53 Sherman JL, Stern BJ. Sarcoidosis of the CNS: comparison of unenhanced and enhanced MR images. AJR Am J Roentgenol 1990; 155 (06) 1293-1301
- 54 Culver DA. Diagnosing sarcoidosis. Curr Opin Pulm Med 2015; 21 (05) 499-509
- 55 Judson MA, Costabel U, Drent M. , et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (01) 19-27
- 56 Kingah P, Alam M, Chugh K, Kamholz J, Samavati L. Role of pulmonary evaluation in diagnosis of neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (03) 209-215
- 57 Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132 (06) 1949-1953
- 58 Schelenz S, Barnes RA, Barton RC. , et al; British Society for Medical Mycology. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. Lancet Infect Dis 2015; 15 (04) 461-474
- 59 Williams WJ. The identification of sarcoid granulomas in the nervous system. Proc R Soc Med 1967; 60 (11, Part 1): 1170-1172
- 60 Manz HJ. Pathobiology of neurosarcoidosis and clinicopathologic correlation. Can J Neurol Sci 1983; 10 (01) 50-55
- 61 Williams III DW, Elster AD, Kramer SI. Neurosarcoidosis: gadolinium-enhanced MR imaging. J Comput Assist Tomogr 1990; 14 (05) 704-707
- 62 Mirfakhraee M, Crofford MJ, Guinto Jr FC, Nauta HJ, Weedn VW. Virchow-Robin space: a path of spread in neurosarcoidosis. Radiology 1986; 158 (03) 715-720
- 63 Dumas JL, Valeyre D, Chapelon-Abric C. , et al. Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. Radiology 2000; 214 (02) 411-420
- 64 Lexa FJ, Grossman RI. MR of sarcoidosis in the head and spine: spectrum of manifestations and radiographic response to steroid therapy. AJNR Am J Neuroradiol 1994; 15 (05) 973-982
- 65 Wengert O, Rothenfusser-Korber E, Vollrath B. , et al. Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci 2013; 335 (1-2): 124-130
- 66 Lower EE, Weiss KL. Neurosarcoidosis. Clin Chest Med 2008; 29 (03) 475-492 , ix
- 67 Jurado R, Walker HK. Cerebrospinal fluid. In: Walker HK, Hall WD, Hurst JW. , eds. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston, MA: Butterworths; 1990
- 68 Komori M, Blake A, Greenwood M. , et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol 2015; 78 (01) 3-20
- 69 Reske D, Petereit HF, Heiss WD. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system--value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 2005; 112 (04) 207-213
- 70 Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol 2015; 285: 1-3
- 71 Khoury J, Wellik KE, Demaerschalk BM, Wingerchuk DM. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist 2009; 15 (02) 108-111
- 72 Petereit HF, Reske D, Tumani H. , et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 2010; 257 (11) 1855-1863
- 73 Chalon MP, Sindic CJ, Laterre EC. Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal. Acta Neurol Scand 1993; 87 (02) 77-82
- 74 Dyck PJ, Albers JW, Wolfe J. , et al; Clinical vs. Neurophysiology Trial 3 Investigators. A trial of proficiency of nerve conduction: greater standardization still needed. Muscle Nerve 2013; 48 (03) 369-374
- 75 Yamakawa KS, Haig AJ, Geisser ME, Tong HC, Chiodo A, Miner JA. The clinician effect on “objective” technical components of the electrodiagnostic consultation. Am J Phys Med Rehabil 2007; 86 (05) 364-372
- 76 Dillingham T, Chen S, Andary M. , et al. Establishing high-quality reference values for nerve conduction studies: a report from the normative data task force of the American Association Of Neuromuscular & Electrodiagnostic Medicine. Muscle Nerve 2016; 54 (03) 366-370
- 77 Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52 (208) 525-533
- 78 Luke RA, Stern BJ, Krumholz A, Johns CJ. Neurosarcoidosis: the long-term clinical course. Neurology 1987; 37 (03) 461-463
- 79 Huang CT, Heurich AE, Sutton AL, Lyons HA. Mortality in sarcoidosis. A changing pattern of the causes of death. Eur J Respir Dis 1981; 62 (04) 231-238
- 80 Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (02) 119-127
- 81 Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol 2007; 64 (05) 691-696
- 82 Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998; 55 (09) 1248-1254
- 83 Wijsenbeek MS, Culver DA. Treatment of sarcoidosis. Clin Chest Med 2015; 36 (04) 751-767
- 84 Lacomis D. Neurosarcoidosis. Curr Neuropharmacol 2011; 9 (03) 429-436
- 85 Teirstein A. Neuromuscular sarcoidosis. Semin Respir Crit Care Med 2002; 23 (06) 505-512
- 86 Nozaki K, Judson MA. Neurosarcoidosis. Curr Treat Options Neurol 2013; 15 (04) 492-504
- 87 Foundation for Sarcoidosis Research. Sarcoidosis treatment guidelines. 2013. Available at: http://do.ready-for-feedback.com/glc/fsr/wp-content/uploads/Treatment-Protocol.pdf . Accessed April 18, 2017
- 88 Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52 (09) 875-879
- 89 Sahoo DH, Bandyopadhyay D, Xu M. , et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38 (05) 1145-1150
- 90 Bitoun S, Bouvry D, Borie R. , et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology 2016; 87 (24) 2517-2521
- 91 Androdias G, Maillet D, Marignier R. , et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76 (13) 1168-1172
- 92 Metyas S, Tawadrous M, Yeter KC, Arkfeld DG. Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab. Int J Rheum Dis 2014; 17 (02) 214-216
- 93 Cohen Aubart F, Bouvry D, Galanaud D. , et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol 2017; 264 (05) 891-897
- 94 Marnane M, Lynch T, Scott J, Stack J, Kelly PJ. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 2009; 256 (01) 139-140
- 95 Lorentzen AO, Sveberg L, Midtvedt Ø, Kerty E, Heuser K. Overnight response to infliximab in neurosarcoidosis: a case report and review of infliximab treatment practice. Clin Neuropharmacol 2014; 37 (05) 142-148
- 96 Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72 (04) 337-340
- 97 Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (02) 91-107
- 98 Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103 (02) 268-273
- 99 Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009; 14 (04) 522-528
- 100 Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104 (03) 760-767
- 101 Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003; 124 (05) 2023-2026
- 102 Travis LB, Curtis RE, Glimelius B. , et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87 (07) 524-530
- 103 Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger Jr TA. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987; 83 (01) 1-9
- 104 Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. The melanocortin system in control of inflammation. Sci World J 2010; 10: 1840-1853
- 105 Berkovich R, Agius MA. Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. Ther Adv Neurol Disorder 2014; 7 (02) 83-96
- 106 Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010; 31 (04) 506-543
- 107 Baughman RP, Barney JB, O'Hare L, Lower EE. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med 2016; 110: 66-72
- 108 Avivi I, Stroopinsky D, Katz T. Anti-CD20 monoclonal antibodies: beyond B-cells. Blood Rev 2013; 27 (05) 217-223
- 109 Lunde S, Kristoffersen EK, Sapkota D. , et al. Serum BAFF and APRIL levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. PLoS One 2016; 11 (08) e0161226
- 110 Sawaya R, Radwan W. Sarcoidosis associated with neuromyelitis optica. J Clin Neurosci 2013; 20 (08) 1156-1158
- 111 Menninger MD, Amdur RJ, Marcus Jr RB. Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol 2003; 26 (04) e115-e118
- 112 Kang S, Suh JH. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Investig 1999; 7 (05) 309-312